PATENT CLAIM ANALYSIS

Application Number: 15892921
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-07
Patent Classification: ["424", "181100"]

Abstract:
Linker toxins and antibody-drug conjugates that bind to human oncology antigen targets such as folate receptor alpha and/or provide anti-tubulin drug activity are disclosed. The linker toxins and antibody-drug conjugates comprise an eribulin drug moiety and can be internalized into target antigen-expressing cells. The disclosure further relates to methods and compositions for use in the treatment of cancer by administering the antibody-drug conjugates provided herein.

Claim (Index 202):
The antibody-drug conjugate of  claim 199 , wherein the cleavable moiety in the linker comprises Val-Cit.

Metadata:
- Claim Count in Document: 31.0
- Percentile: 88.0
- Lexical Diversity: 1.25926
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15448497', '14205915', '15284444', '14204023', '14774512']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7851289333607646
- 35 USC 102 Novelty (BERT): 0.6970616525381724
- Combined Prediction Score: 0.7763222052785054
- Mean Citation Score: 509.29023000000007
- Max Citation Score: 1018.4353
- Similarity Product: 738.0713263380645

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test